MENU
+Compare
GANX
Stock ticker: NASDAQ
AS OF
Nov 13, 04:59 PM (EDT)
Price
$2.98
Change
+$0.03 (+1.02%)
Capitalization
106.05M

GANX Gain Therapeutics Forecast, Technical & Fundamental Analysis

Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology... Show more

GANX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
a Summary for GANX with price predictions
Nov 12, 2025

GANX in upward trend: price rose above 50-day moving average on November 06, 2025

GANX moved above its 50-day moving average on November 06, 2025 date and that indicates a change from a downward trend to an upward trend. In of 36 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on November 10, 2025. You may want to consider a long position or call options on GANX as a result. In of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for GANX just turned positive on November 10, 2025. Looking at past instances where GANX's MACD turned positive, the stock continued to rise in of 47 cases over the following month. The odds of a continued upward trend are .

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where GANX advanced for three days, in of 222 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The RSI Indicator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.

The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where GANX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

GANX broke above its upper Bollinger Band on November 10, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for GANX entered a downward trend on November 07, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. GANX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (28.653) is normal, around the industry mean (24.439). P/E Ratio (0.000) is within average values for comparable stocks, (63.753). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.001). Dividend Yield (0.000) settles around the average of (0.046) among similar stocks. P/S Ratio (625.000) is also within normal values, averaging (322.723).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GANX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
GANX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published Earnings

GANX is expected to report earnings to rise 16.60% to -17 cents per share on March 19

Gain Therapeutics GANX Stock Earnings Reports
Q4'25
Est.
$-0.17
Q3'25
Est.
$-0.15
Q2'25
Missed
by $0.02
Q1'25
Beat
by $0.03
Q4'24
Beat
by $0.10
The last earnings report on November 12 showed earnings per share of -15 cents, meeting the estimate of -15 cents. With 1.43M shares outstanding, the current market capitalization sits at 106.05M.
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
4800 Montgomery Lane
Phone
+1 301 500-1556
Employees
32
Web
https://www.gaintherapeutics.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
VVVNF3.610.37
+11.42%
Vivendi SE
AGTX0.04N/A
+0.72%
Agentix Corp.
TRMLF44.590.16
+0.36%
Tourmaline Oil Corp.
DYFSF0.08N/A
N/A
Dynacert Inc
IMMQF3.46N/A
N/A
IMMOBILIARE GRANDE DISTRIBUZIONE SIIQ SPA

GANX and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, GANX has been loosely correlated with COYA. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if GANX jumps, then COYA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GANX
1D Price
Change %
GANX100%
+10.07%
COYA - GANX
42%
Loosely correlated
+1.33%
COGT - GANX
38%
Loosely correlated
+5.51%
TRDA - GANX
38%
Loosely correlated
+4.03%
ELVN - GANX
37%
Loosely correlated
+3.36%
IRD - GANX
37%
Loosely correlated
-2.54%
More